Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bone marrow mononuclear cells (BM-MNCs) is an investigational cell therapy being developed by Universitas Indonesia and Dr. Cipto Mangunkusumo National General Hospital for the treatment of type 2 diabetes mellitus. The therapy involves harvesting mononuclear cells from the patient's own bone marrow and delivering them via intra-pancreatic catheterization. The mechanism of action is centered on the potential of these cells to promote the regeneration of pancreatic beta-cells, reduce insulin resistance, and enhance endogenous insulin secretion, thereby improving glycemic control in patients who have not achieved adequate results with standard treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Universitas Indonesia).